🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

‼️PhD Position now available in my lab‼️ Do you like: * Neurodegenerative disease? * Neuroimaging and/or multi-omics? * AI and data-driven life science? Want to work with RikOssenkoppele Alexandra Young and Laura Wisse? Apply here: lu.varbi.com/what:job/jobID… Please rt/share 🙏

🚨New publication in Nature Medicine, co-led with Kanta Horie🚨 Huge step towards an accurate and scalable diagnosis for #Alzheimer's disease. In this study, we validated the novel MTBR-tau243 biomarker in plasma🩸 A short 🧵

In a head-to-head comparison, plasma p-tau217 and tau-PET imaging equally predict which healthy people will develop mild cognitive impairment. Still, using both could streamline selection for clinical trials. Lund University Amsterdam UMC ow.ly/sp8h50VvgsI

New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in Nature Medicine: nature.com/articles/s4159…. A thread🧵

6⃣We conclude that this fully automated plasma p-tau217 test demonstrates high accuracy for identifying AD pathology across centers and settings using predefined cutoffs. The study highlighted its ability to serve as a scalable, cost-effective diagnostic tool for diagnosing AD.💪🏼

Big, big thanks to all collaborators and co-authors, especially the Gothenburg, Barcelona, and Brescia teams! Sebastian Palmqvist Noëlle Warmenhoven Nicholas Ashton Marc Suárez-Calvet 🧠🧪 🩺🌈 Oskar Hansson BioFINDER

Plasma eMTBR-tau243 is a specific #biomarker of #tau tangles in #Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment. #NeurodegenerativeDiseases #AlzheimersAwareness #Biomarkers nature.com/articles/s4159…

Among 1,767 patients in 5 centers, a fully automated blood test showed high accuracy for Alzheimer’s pathology in secondary and primary care using a predefined cutoff. nature.com/articles/s4159…

🚨New paper alert! Research from our group and collaborators at University of Melbourne shows increased speed of neuronal aging in schizophrenia- the same phenomena was not seen in bipolar disorder. 📖Read more here: theconversation.com/brains-of-peop…

A new, simpler and cheaper analytical method for #Alzheimers disease could help bring #blood tests into the #healthcare system globally, according to a new study led by Sebastian Palmqvist, Oskar Hansson and Noëlle Warmenhoven from 🇸🇪 Lund University. dlvr.it/TKH96w

Our research on altered empathy processing in frontotemporal dementia was recently featured in The Conversation! Great to see this important work reaching a wider audience. 🔗theconversation.com/loss-of-empath… 📖Check out the original publication 👇

🧠Exciting new findings from a great collaboration between the BioFINDER study and the talented Caly Yu Xiao (肖燏) from Jake Vogel group!! In their preprint, they show that tau presence and tau load are guided by unique brain mechanisms. Dive into the details here 👇

Scientists use tau pathology markers in plasma and CSF to stage #alzheimersdisease. This could help identify and monitor people who might benefit from therapy. Göteborgs universitet / University of Gothenburg McGill University Lund University @wustl ow.ly/saTg50VH4zj

‼️New preprint! We are happy to share our latest work led by Toomas Erik Anijärv 🇪🇪 investigating why tau pathology in Alzheimer’s disease (AD) often accumulates more in one hemisphere of the brain than the other. Check out🔗biorxiv.org/content/10.110… or dive into the details below👇

6/🧵Our findings suggest that regional vulnerability to Aβ, not reduced inter-hemispheric connectivity, drives asymmetric tau accumulation in AD. This strengthens the link between Aβ and tau and supports the evidence of early anti-Aβ interventions to help limit tau buildup.

Big thanks to all co-authors and collaborators! RikOssenkoppele Ruben Smith Lyduine Collij Harry H Behjat Jonathan Rittmo Linda Karlsson Danielle van Westen Jake Vogel Erik Stomrud Sebastian Palmqvist Niklas Mattsson-Carlgren Nicola Spotorno Oskar Hansson + those not on X

Immunoassay choice for #pTau217 is important! In this study, we show that LMW #pTau217 is more specific to Alzheimers pathology than HMW #pTau217 immunoassay designs – which can give false-positives. alz-journals.onlinelibrary.wiley.com/doi/10.1002/al… BioFINDER Oskar Hansson

🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇pmc.ncbi.nlm.nih.gov/articles/PMC12…

Individuals with more severe clinical Alzheimer disease symptoms than their biological stage often have additional pathologies. ja.ma/3H0b6TU

🚨Exciting new preprint from a great collaboration between our group and the talented PhD student Jonathan Rittmo from Jake Vogel's group! They investigate how the 🧠 reorganises in the context of age and AD. Dive into the details here 🧵👇